Amgen has announced plans to invest an additional USD 300 million in its US manufacturing network to further advance US-based production capacity, enhance next-generation technologies and support a reliable supply of medicines for patients.

Robert A. Bradway, Chairman and Chief Executive Officer (CEO), Amgen, said, "Amgen has been a leader in US biomanufacturing for decades, and this expansion reflects our continued commitment to American manufacturing. By growing our operations in Puerto Rico, we are ensuring patients have access to the medicines they need, investing in the long-term strength of our domestic supply chain and supporting American jobs."

Amgen's expansion of its biologics manufacturing facility in Puerto Rico will strengthen existing advanced manufacturing roles, support workforce development across the region and generate hundreds of construction jobs. Established in 1992, the company's Juncos site is one of the largest and most advanced biomanufacturing facilities in the world, producing biologic medicines distributed to over 60 countries.

Amgen's latest investment builds on its broader US manufacturing expansion strategy. Over the past year, the company has announced planned investments of USD 650 million in Puerto Rico, USD 9 million in Ohio and USD 600 million in a science and innovation center in California. In addition, the company has invested over USD 1.5 billion in North Carolina.

Jenniffer González Colón, Governor, Puerto Rico, said, "This investment confirms that the policies we have implemented are working. Puerto Rico has more than 60 years of excellence in the biopharmaceutical sector, supported by a highly skilled workforce and world?class infrastructure, and Amgen knows this better than anyone. We will continue working to make Puerto Rico the number one destination for advanced manufacturing in the United States."

Amgen's long-standing commitment to US innovation and state-of-the-art operations is reflected in over USD 40 billion invested in manufacturing and research and development since the enactment of the Tax Cuts and Jobs Act (TCJA) of 2017. Pro-growth tax policies in TCJA, extended and reinforced by the One Big Beautiful Bill Act of 2025, support the company's ability to invest in domestic science and manufacturing.

Sebastián Negrón Reichard, Secretary, Department of Economic Development and Commerce, Puerto Rico, said, "Amgen's additional USD 300 million commitment in Juncos is a powerful signal that the future of American biomanufacturing is being built here. Combined with the USD 650 million previously announced, this represents nearly USD 1 billion in confidence in our workforce, our capabilities and our ability to produce life?saving medicines This is the result of our commitment to building a pro?business jurisdiction where world?class companies like Amgen can grow, invest and thrive."